Alnylam Pharmaceuticals’ stock surged by more than 35% following positive results from a late-stage clinical trial of its heart drug. The drug, known as vutrisiran, demonstrated significant effectiveness in reducing death rates and recurring heart events. Whether used in combination with the standard treatment or as a standalone option, vutrisiran showed promising outcomes in a Phase 3 trial. These findings have generated much excitement among investors, leading to a substantial increase in Alnylam Pharmaceuticals’ stock.
